Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
5.85
-0.05 (-0.85%)
At close: Jun 27, 2025, 4:00 PM
6.13
+0.28 (4.79%)
After-hours: Jun 27, 2025, 7:41 PM EDT
Coya Therapeutics Stock Forecast
Stock Price Forecast
According to 3 professional analysts, the 12-month price target for Coya Therapeutics stock ranges from a low of $14 to a high of $18. The average analyst price target of $16.67 forecasts a 184.96% increase in the stock price over the next year.
Price Target: $16.67 (+184.96%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Coya Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +207.69% | Jun 9, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $14 | Strong Buy | Maintains | $14 | +139.32% | May 13, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $14 | Strong Buy | Maintains | $14 | +139.32% | Apr 28, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $18 | Strong Buy | Maintains | $18 | +207.69% | Apr 24, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $18 | Strong Buy | Maintains | $18 | +207.69% | Apr 22, 2025 |
Financial Forecast
Revenue This Year
7.36M
from 3.55M
Increased by 106.97%
Revenue Next Year
510.00K
from 7.36M
Decreased by -93.07%
EPS This Year
-1.22
from -0.98
EPS Next Year
-1.87
from -1.22
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 9.6M | 1.6M | 15.8M | ||
| Avg | 7.4M | 510,000 | 12.8M | ||
| Low | 2.4M | n/a | 9.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 168.8% | -78.6% | 2,988.2% | ||
| Avg | 107.0% | -93.1% | 2,400.0% | ||
| Low | -33.8% | - | 1,821.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.78 | -1.51 | -0.68 | ||
| Avg | -1.22 | -1.87 | -0.85 | ||
| Low | -1.54 | -2.26 | -1.00 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.